Home
Browse
Search
Statistics
About
Usage
PMID: 21607646
Venerando A, Pagano MA, Tosoni K, Meggio F, Cassidy D, Stobbart M, Pinna LA, Mehta A
Understanding protein kinase CK2 mis-regulation upon F508del CFTR expression.
Naunyn Schmiedebergs Arch Pharmacol. 2011 May 24., 2011-05-24
[PubMed]
Sentences
No.
Mutations
Sentence
Comment
74
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:74:98
status:
NEW
view ABCC7 p.Gly551Asp details
As proof of principle, a new small molecule has recently been reported to re-open the rare mutant
G551D
CFTR (<5% of alleles) which theoretically cannot transport anions because its nucleotide sandwich is defective in ATP hydrolysis (Accurso et al. 2010).
Login to comment
75
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:75:93
status:
NEW
view ABCC7 p.Gly551Asp details
In CF, the affected sweat gland duct produces too much sodium and chloride because defective
G551D
CFTR cannot open its pore to re-absorb chloride which consequently, together with luminal sodium, passes on by the chloride-impermeant apical membrane of the sweat duct onwards to the skin surface.
Login to comment
77
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:77:203
status:
NEW
view ABCC7 p.Gly551Asp details
That the observed LIMBO reversal is not complete suggests that the pathway from gene to disease is not fully understood and is consistent with this drug`s unexpected effects on CFTR mutants without this
G551D
-induced ATP hydrolytic defect.
Login to comment
79
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 21607646:79:140
status:
NEW
view ABCC7 p.Gly542* details
This drug is claimed to restore full-length CFTR bearing stop mutations that normally induce nonsense-mediated CFTR decay (for example, the
G542X
stop mutation in CFTR and others like it that together account for about 10% of CFTR mutants).
Login to comment
80
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 21607646:80:103
status:
NEW
view ABCC7 p.Gly542* details
At the very least, this drug, which was developed to create read-through at single stop codons such as
G542X
, should reverse the above 'gold standard` sweat test, but it absolutely fails to do so, thus adding further doubt to our ability to fully understand the path from CFTR defect to disease.
Login to comment
98
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:98:125
status:
NEW
view ABCC7 p.Gly551Asp details
This idea is challenged by a recent study (Comer et al. 2009) examining lung function in CF patients with the above 'severe`
G551D
CFTR mutant that is supposedly devoid of any channel activity (Briel et al. 1998) in vitro.
Login to comment
102
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:102:72
status:
NEW
view ABCC7 p.Gly551Asp details
Thus, we have yet another theory-practice paradox of a dead but present
G551D
CFTR channel that is normally processed to the apical membrane creating better functioning lungs than those with a F508del CFTR missing channel that is degraded in the ER and probably never reaches the apical membrane.
Login to comment
103
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:103:76
status:
NEW
view ABCC7 p.Gly551Asp details
At the very least, these patient data challenge the widely held notion that
G551D
is always a 'severe` CF mutation.
Login to comment
104
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:104:90
status:
NEW
view ABCC7 p.Gly551Asp details
Those proposing the alternative 'knock-in` network dysfunction model would say that after
G551D
mutation, the sodium channel may not be as hyperactive as found in F508del CFTR, so we might expect better lungs.
Login to comment
105
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 21607646:105:24
status:
NEW
view ABCC7 p.Gly551Asp details
Yet others suggest that
G551D
CFTR also fails to inhibit the sodium channel in model systems (Briel et al. 1998), and the latest animal data suggest that the very idea of augmented sodium absorption needs to be treated with caution rather than drugs (Chen et al. 2010).
Login to comment